Comai S
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
ArticlePsilocybin
Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.
ArticlePsychedelics
Sex-sensitive serotonergic signaling in psychedelic pharmacology.
ArticlePsilocybin
Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible <i>N</i>-Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure.
ArticlePsilocybin
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.
ArticlePsilocybin
Emerging mechanisms of psilocybin-induced neuroplasticity.
ArticlePsilocybin
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
ArticleLSD
Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT<sub>2A</sub> receptor.
ArticleLSD
Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome.
ArticleLSD
Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.
ArticleLSD
Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice.
ArticleLSD
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission.
ArticleLSD